((1S,2R)-1-(3-allyloxy-benzyl)-3-{benzyloxycarbonyl-[1-(3-isopropyl-phenyl)-cyclopropyl]-amino}-2-hydroxy-propyl)-carbamic acid tert-butyl ester | 943923-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((1S,2R)-1-(3-allyloxy-benzyl)-3-{benzyloxycarbonyl-[1-(3-isopropyl-phenyl)-cyclopropyl]-amino}-2-hydroxy-propyl)-carbamic acid tert-butyl ester
• 英文别名: benzyl N-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-(3-prop-2-enoxyphenyl)butyl]-N-[1-(3-propan-2-ylphenyl)cyclopropyl]carbamate
• CAS: 943923-93-1
• 化学式: C₃₈H₄₈N₂O₆
• 分子量: 628.809
• InChiKey: SUIWCLHGCRVHIN-SZAHLOSFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  46
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ((1S,2R)-1-(3-allyloxy-benzyl)-3-{benzyloxycarbonyl-[1-(3-isopropyl-phenyl)-cyclopropyl]-amino}-2-hydroxy-propyl)-carbamic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到C₃₃H₄₀N₂O₄
  参考文献：
  名称：

  Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application

  摘要：

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.092
• 作为产物：
  描述：

  、 氯甲酸苄酯 在 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 以100%的产率得到((1S,2R)-1-(3-allyloxy-benzyl)-3-{benzyloxycarbonyl-[1-(3-isopropyl-phenyl)-cyclopropyl]-amino}-2-hydroxy-propyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application

  摘要：

  A series of macrocyclic peptidic BACE-1 inhibitors was designed. While potency on BACE-1 was rather high, the first set of compounds showed poor brain permeation and high efflux in the MDRI-MDCK assay. The replacement of the secondary benzylamino group with a phenylcyclopropylamino group maintained potency on BACE-1, while P-glycoprotein-mediated efflux was significantly reduced and brain permeation improved. Several compounds from this series demonstrated acute reduction of Ab in human APP-wildtype transgenic (APP51/16) mice after oral administration. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.092

文献信息

• MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS
  申请人：Betschart Claudia

  公开号：US20090029960A1

  公开（公告）日：2009-01-29

  The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  该发明涉及一种新型的大环化合物，其公式如下，在自由碱基形式或酸盐形式下，其中所有变量如规范中所定义，其制备方法，用作药物的方法以及包含它们的药物。
• WO2007/77004
  申请人：——

  公开号：——

  公开（公告）日：——
• MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS
  申请人：Novartis AG

  公开号：EP1968954A1

  公开（公告）日：2008-09-17
• US8039455B2
  申请人：——

  公开号：US8039455B2

  公开（公告）日：2011-10-18
• [EN] MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS<br/>[FR] COMPOSES MACROCYCLIQUES UTILISES COMME INHIBITEURS DE BACE
  申请人：NOVARTIS AG

  公开号：WO2007077004A1

  公开（公告）日：2007-07-12

  [EN] The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
  [FR] L'invention concerne de nouveaux composés macrocycliques de formule (I), dans laquelle toutes les variables sont telles que définies dans la spécification, dans une forme de base libre ou dans une forme saline d'addition acide, leur préparation, leur utilisation en tant que médicaments et des médicaments les renfermant.